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Summary In this study, 44 primary or metastatic human ovarian tumours were tested for allelic deletions on
the short arm of chromosome 11. Analysis of 12 polymorphic loci by Southern blotting evidenced loss of
heterozygosity (LOH) in at least one locus in 41% of cases. Moreover, two hot spots of deletions were
tentatively mapped on lIpl3 and lp15.5. Our results demonstrated that LOH at lIp is a common event in
ovarian carcinomas and were indicative of the possible existence in lip of two oncosuppressor genes involved
in ovarian carcinogenesis. The similarity observed with lIp allelic losses in Wilms tumours, clustered in lIpl3
and lp15.5 too, suggests that deletion and possibly inactivation of the same growth regulatory genes (WT
genes) could also contribute to development of the malignant phenotype in ovarian carcinomas. Finally, a
statistically significant association (P = 0.005) between I lp deletions and hepatic involvement was suggested by
the analysis ofdistribution of lIp LOH relative to different clinical and pathological parameters of the tumour
patients.
Ovarian cancer is the major cause of death in individuals
with gynaecologic tumours. Relatively little is known about
the molecular events associated with the development and
subsequent progression and metastasis of epithelial ovarian
tumours.
Genetic changes found in ovarian cancer include activation
of oncogenes (van't Veer et al., 1988; Zhou et al., 1988; Boltz
et al., 1989; Slamon et al., 1989; Enomoto et al., 1991) and
allelic losses, reflecting a possible inactivation of tumour
suppressor genes. In particular, loss of heterozygosity (LOH)
at the short arm of chromosome 11 was reported as a very
common event (Ehlen & Dubeau, 1990; Lee et al., 1990; Viel
et al., 1991), but also frequent allelic losses of genes mapped
on chromosomes 3, 6, 13 and 17 were described (Eccles et al.,
1990; Ehlen & Dubeau, 1990; Lee et al., 1990; Russel et al.,
1990; Li et al., 1991; Okamoto et al., 1991).
Tumour suppressor genes on chromosome Ilp seem to be
involved in several other malignancies, including bladder
(Fearon et al., 1985), breast (Ali et al., 1987; Mackay et al.,
1988), lung (Weston et al., 1989; Ludwig et al., 1991) and
adrenocortical (Henry et al., 1989) carcinomas; testicular
cancers (Lothe et al., 1989); Wilms tumours (Reeve et al.,
1989; Wadey et al., 1990); hepatoblastomas (Koufos et al.,
1985) and Rhabdomyosarcomas (Scrable et al., 1987). Allelic
losses on lip, sometimes concurrent with LOH at a number
of different chromosomes, may affect certain unknown genes,
providing selective growth advantages and leading to a fur-
ther destabilisation of the genome (Devilee et al., 1991). In a
subset of Wilms tumours the oncosuppressor gene involved
in the LOH at lip has been identified: losses or functional
inactivations of the WT-1 gene, mapping on lIpl3, are
associated with both genetic predisposition (in hereditary
cases) and tumourigenesis (Haber et al., 1990; Gessler et al.,
1990; Pelletier et al., 1991a; Pelletier et al., 1991b). However,
linkage analysis and deletion mapping studies on lip sug-
gested the presence of another critical Wilms tumour gene on
11p15.5 (Koufos et al., 1989; Reeve et al., 1989; Wadey et al.,
1990), but the putative WT-2 gene has not yet been iden-
tified.
At the present it is unknown if WT genes are growth
regulatory genes also involved in the aetiology of other
tumours displaying Ilp LOH. The only report suggesting
WT-1 function abrogation in non Wilms tumour malig-
nancies, described WT-1 mutation in a juvenile granulosa cell
tumour from a Denys Drash individual (Pelletier et al.,
1991a).
In the present study we determined the incidence of allelic
deletions on chromosome lp in a large number of primary
and metastatic ovarian tumours and we discuss the possible
clinical pathological significance. Through the analysis of 12
polymorphic loci we also present preliminary data on the
existence of two hot spots of deletions.
Material and methods
Patients and tissues
This study considered 41 patients affected by ovarian car-
cinoma (median age 57.3, range 25-77) that underwent
surgery at the Department of Gynaecological Oncology at
the Centro Riferimento Oncologico in Aviano (Pordenone,
Italy).
Forty-four tumour samples and normal pelvic tissues
(usually from abdominal wall) and/or peripheral blood were
collected during surgery from these 41 patients (three ofthem
were considered twice in this study because of a relapse of
their cancer). The material to be analysed was selected by a
pathologist to ensure that the neoplastic samples were macro-
scopically entirely tumours. Twenty-six patients underwent
first surgery after clinical and instrumental diagnosis; three of
them and the other 15 patients (for a total of 18 surgical
interventions) underwent surgical reexploration for relapse of
disease after initial surgery and eventual first line
chemotherapy.
All patients studied and related major clinicopathological
data are listed in Table I.
Southern blot analysis andprobes
High molecular weight DNA was prepared from tumour and
normal specimens by standard methods (Sambrook et al.,
1989). DNA restriction, electrophoresis in agarose gel, hy-
bridisation and washing conditions were as previously des-
cribed (Viel et al., 1990). The DNA probes used in this study
are listed in Table II. DNA probes were 32P-labelled by the
multiprime labelling system (Amersham, Buckinghamshire,
UK) at specific activity> I09 cpm tg-I DNA. The hybridised
membranes were exposed to X-ray films with an intensifying
screen at -80°C and the intensity of autoradiographic sig-
nals was determined by densitometric scanning (ISCO, Inc,
Nebraska, USA).
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Table 1 Clinicopathological characteristics of ovarian tumour patients
Twnoura
specimen Histological' Hepaticd
Case analysed type Gradec metastasis JJpLOH
1-SA OM M G3 no yes
2-GM OV S G3 no no
3-DM OV S G2 no yes
4-TA ABD S G2 yes yes
5-BM OV E G2 yes (gb) yes
6-FL OV S G3 no no
7-RR OV S G3 no no
8-RR ABD S G3 yes yes
9-TT OV S G2 no no
10-NB L E G3 yes yes
11-SE OM E G2 no no
12-NC OV S G3 no no
13-ZE OV E G3 no yes
14-ZE P E G3 yes yes
15-PC OM UND G3 no no
16-RA P UND G2 no no
17-RA P UND G2 no no
18-DG OV S G3 no yes
19-SA OM S UNK no no
20-HV P UND G3 no no
21-GM OM S G3 no no
22-GA OM S G2 no no
23-FJ OM S G2 yes yes
24-PA OM S G2 no no
25-VB p S G2 no no
26-PE OV UND G3 yes yes
27-BA ABD S G3 no no
28-ZF ABD S G3 yes yes
29-Fl OM S G3 yes no
30-TV p S G3 no no
31-PG OV S G3 no no
32-PI OM UND G2 no no
33-ME I UND G3 no no
34-CR S UND G3 no no
35-GC OV E G2 yes no
36-DR OV S GI no no
37-RD ABD S G3 yes yes
38-VC OM UND G3 yes (gb) no
39-GL OM S G3 no yes
40-PL OM S G2 yes (gb) yes
41-RL OV E G3 no no
42-MM P UND G3 no yes
43-SP I S G3 no yes
44-BG OV E G3 yes yes
aOM, omentum; 0, ovary; ABD, abdominal metastasis; L, liver; P, peritoneum; I, intestine; S,
skin. bM, mesothelioma of ovarian origin; S, serous; E, endometrioid; UND, undifferentiated
adenocarcinoma. CUNK, unknown. dyes (gb), only gall bladder metastasis.
Table II DNA probes used to detect lIp RFLPs
Locus Location Probe (Reference) Insert (kb) RFLP (kb)
Ha-rasl 1lpl5.5 p344 (Pulciani et al., 1982) BamHI (6.6) BamHI (7.8-7.6-7.2-6.7-6.6) IGF-2 1lpl5.5 phins3l1 (Xiang et al., 1987) EcoRI (8.6) BamHI (2.2-1.2) Insulin llpl5.5 phins31o (Bell et al., 1981) BamHI (0.88) TaqI (7.4-6.1-5.4-4.6) Dl S12 1 IpI5.5 pADJ762 (Barker et al., 1984) EcoRI (5.5) TaqI (8.3-3.2) P Globin IlplS.5 pp Globin PstI (4.4) BamHI (22-8.3) A7 Globin 1 IpI5.5 py Globin Hindlll (3) Hindlll (3.5-2.7) G' Globin 1 Ipl5.5 py Globin HindlIl (3) HindIII (8-7.2) Calcitonin 1lpl5.4 pEMBL36 (Hoppener et al., 1984) PstI (0.66) TaqI (8-6.5) DlIS17 11pl3 pJl9.4 (Housman et al., 1985) BamHI-EcoRI (2.1) BamHI (21-13) P-FSH Ilpl3 pSHc-7 (Watkins et al., 1987) HinclI-SacI (0.5) HindlIl (14-12) DllS16 llpl3 P32-1 (Feder et al., 1985) EcoRI (8.9) MspI (11-7.6+6+4-6+4+3) Catalase llpl3 pINT-800 (Quan et al., 1985) EcoRI-PstI (0.8) TaqI (3.5 - 2.5 + 1)
Statistical analysis morphisms (RFLP) of 12 genomic regions on lIp. In three
The x2 and the Fisher's exact (two sided) tests were used for patients we had the chance of analysing two tumoural sam-
statistical analysis of the results. ples, obtained from two successive surgical interventions (patient RR, ZE and RA). Of the 12 polymorphic loci, seven
have been mapped to chromosome region 1 Ip15.5, 1 to Results llpl5.4 and 4 to llpl2 (Table II). All patients were
heterozygous, and thus informative, in at least one locus on Paired samples of the 41 patients were analysed with 11 chromosome llp. In every case DNA restriction fragments probes that detected Restriction Fragment Length Poly- of the expected size were seen (Table II).1032 A. VIEL et al.
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Figure 1 Representative autoradiograms, from Southern blot analyses, demonstrating LOH at the lIp loci tested. Tumour DNA
(left lane) and constitutional DNA of the same patient (right lane) are shown. Numbers to the right of autoradiograms indicate the
molecular size of the allelic fragments in kilobases. Arrows indicate the allelic fragment lost in the tumour DNA sample.
Dimensions of the eventual constant bands are reported in parenthesis. The additional unindicated bands revealed by P Globin and
Calcitonin probes correspond to cross-hybridising partially homologous DNA sequences. Both Ay and G7 Globin genes can been
seen in the same lane.
In the analysis of the tumour specimens all the poly-
morphic probes used were able to detect loss or significant
reduction (at least 50%) in autoradiographic signal for one
of the restriction fragments, indicating LOH in the corres-
ponding locus (Figure 1). Frequencies of LOH were 47%
(9/19 informative) for Ha-rasl, 43% (6/14) for IGF2, 35%
(7/20) for Insulin, 50% (2/4) for DlIS12, 25% (4/16) for P
Globin, 15% (2/13) and 36% (5/14) for A" Globin and G7
Globin respectively, 40% (6/15) for Calcitonin, 35% (6/17)
for DllS17, 29% (7/24) for P-FSH, 26% (6/23) for DllS16
and 25% (6/24) for Catalase. A total of 18 tumour samples
from 17 ovarian cancer patients displayed LOH in at least
one locus (Table III) and thus the overall incidence of this
phenomenon was 41% (18/44 tumours analysed). However,
this frequency represents a minimum estimation of this
phenomenon and it can not be excluded that, in some
patients, the high percentage of constitutional homozygosity
observed (Table III) could have masked other deletion
regions. Of the 18 deleted tumours, 11 remained heterozy-
gous for at least one I lp locus. No evidence was obtained of
homozygous deletions.
The presumed maximum extent of DNA sequence deletion
on the short arm of chromosome 11 for the 18 deleted
tumours can be deduced from Figure 2. In eight tumours
(3-DM, 5-BM, 26-PE, 37-RD, 39-GL, 42-MM, 43-SP and
44-BG) LOH might extend from Ha-rasl locus to P-FSH or
Catalase loci and thus a wide deletion presumably encom-
passed a large portion of chromosome 11 including regions
lIplS.5 and lIpl3. In tumour 10-NB, in which LOH was
evidenced only at GI Globin and Calcitonin loci, a more
restricted deletion region possibly extended from the cen-
tromeric portion of lIp15.5 to the telomeric portion of
llpl3. In four of the remaining cases (1-SA, 4-TA, 14-ZE
and 18-DG) LOH at the informative loci mapping on lp13
were not observed and thus deletions seemed to involve only
chromosome band pI5. On the contrary, in another two
cases (23-FJ and 28-ZF), heterozygosity was lost for the
informative loci on llpl3, but maintained on lIpl5. Finally
in the last three tumour samples (8-RR, 13-ZE and 40-PL)
two regions of deletions were separated by sequences in
which heterozygosity was conserved. This analysis suggests
the presence of two hot spots of deletion in ovarian tumours.
The minimum extent of the first one, on llpl3, was defined
by tumours 13-ZE and 40-PL and appeared to involve a
short region between DI1IS16 and Catalase loci. The
minimum extent of the second one, on llpl5.5, was defined
by tumours 8-RR and 40-PL in which deletions may extend
from Ha-rasl to , Globin gene.
Two sequential samples were examined from three patients
(Table I; Figure 2). Patient RR displayed lp allelic losses in
metastasis (8-RR), but not in primary tumour (7-RR); on the
contrary both metastic tissues (16-RA and 17-RA) obtained
sequentially from patient RA did not reveal any reductions
to homozygosity; finally LOH was evidenced both in the
primary site of tumour (13-ZE) and abdominal metastasis
(14-ZE) from patient ZE. Interestingly in this last patient
distinct allelic loss patterns were displayed by the two tumour
samples analysed, indicating that different cell populations
originated and expanded during the evolution of disease.
We determined the distribution of lip deletions relative to
different clinical and pathological parameters characterising
the tumour, the patients age, hystological type, cytological
differentiation grade, metastasis of the disease to the liver,
gallbladder, retroperitoneal lymph nodes and extracoelomic
tissues, positivity of washing, surgical and chemotherapeutic
pretreatment and survival (data not shown). Among the
numerous data considered, loss of lip polymorphic loci only
associates significantly with hepatic involvement at surgery.
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Table HI Details of the allelic analysis of ovarian tumours
Case Ha-rasl IGF2
1-SA 0 LOH
2-GM 0 NT
3-DM LOH 0
4-TA LOH 0
5-BM LOH LOH
6-FL 0 NT
7-RR 0 E
8-RR 0 LOH
9-TT E NT
10-NB 0 E
I I-SE E NT
12-NC 0 NT
13-ZE LOH 0
14-ZE LOH 0
15-PC E NT
16-RA 0 0
17-RA 0 0
18-DG 0 0
19-SA 0 NT
20-HV E 0
21-GM 0 0
22-GA E E
23-FJ 0 0
24-PA E NT
25-VB 0 NT
26-PE 0 0
27-BA 0 NT
28-ZF 0 0
29-FJ E 0
30-TV 0 0
31-PG 0 0
32-PI E 0
33-ME E E
34-CR E 0
35-GC 0 0
36-DR 0 E
37-RD 0 LOH
38-VC 0 E
39-GL LOH LOH
40-PL LOH 0
41-RL 0 E
42-MM LOH LOH
43-SP LOH 0
44-BG 0 0
0, homozygous patients; E,
heterozygosity in their tumour;
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no allelic loss in their tumour; LOH, heterozygous patients with loss of
In fact 11 out of 18 deleted tumour samples (61%) were
obtained from patients with liver and/or gallbladder metas-
tasis; on the contrary only three out of the 26 non deleted
tumours (11%) were derived from patients with an infiltrated
liver and/or gallbladder (Table I). The difference between the
two groups (deleted and non deleted tumours) was statis-
tically significant (X2 corrected = 9.872, P = 0.002). By con-
sidering only liver infiltration, 9/18 and 2/26 were observed
to be positive. This difference was also significant (x2 cor-
rected = 8.023, P = 0.005).
Discussion
Deletions on the short arm ofchromosome 11 are considered
as a common and important event in the development and/or
progression of many cancers. Such allelic deletions, in fact,
could involve loss of a tumour suppressor gene within the
affected region of the chromosome (Marshall, 1991). Other
studies reported I lp deletions in ovarian tumours with non-
random frequencies of 30-50% (Ehlen & Dubeau, 1990; Lee
et al., 1990; Zheng et al., 1991). In our previous study we
found Ha-rasI allelic loss in four out of seven informative
cases and, Ha-rasI mutations being absent, we could exclude
a loss of competitive effect of mutated versus wild type ras
allele (Viel et al., 1991). In this much wider series of ovarian
tumours several other genes located centromeric to Ha-rasI
locus on lIp were also analysed in order to determine the
extension of the chromosome deletion.
The frequency of Ilp LOH found in our ovarian car-
cinoma samples (at least 41%) is similar or even higher than
those previously reported for Wilms and other tumours
(Fearon et al., 1985; Ludwig et al., 1991; Mackay et al., 1988;
Reeve et al., 1989) and is likely to reflect somatic events
specifically involved in tumourigenesis. Deletion affecting
chromosome lp were not so frequent in the study of Sato et
al. (24%), but the reason for this apparent discrepancy might
be consequent upon the different number and type of the loci
tested (Sato et al., 1991). Furthermore our data indicate the
existence of two hot spots of gene deletion on the short arm
of chromosome 11, similarly to that described for Wilms
tumours (Reeve et al., 1989; Wadey et al., 1990) and lung
carcinomas (Weston et al., 1989; Ludwig et al., 1991).
The first hot spot of gene deletion in ovarian carcinomas,
mapping on band 1 lpl3 between Dl1IS16 and Catalase loci,
corresponds to the chromosome location of the WT-1 gene
(Rose et al., 1990). WT-1 gene encodes a putative transcrip-
tion factor implicated in nephrogenesis and gonad develop-
ment (Pelletier et al., 1991c). Its involvement in urogenital
development might explain the urogenital defects observed
among hereditary cases of Wilms tumour patients. Moreover,
deletions and/or sequence abnormalities of this gene have
been described in Wilms tumours, those that have developed
sporadically and those in individuals affected by WAGR1034 A. VIEL et al.
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Figure 2 Extents of allelic deletions in the ovarian tumours. In the upper part of the figure the 18 tumours showing lp LOH are
recorded; in the lower part of the figure the sequential tumour samples obtained from three patients are shown. Grey bars indicate
regions where heterozygosity was retained; solid bars indicate deleted regions, whilst homozygous non informative and non tested
sequences are represented by open bars. Position and extension of I1pl5.5 a, and llp13 b, hot spots of deletion are indicated on
the top.
(Wilms tumour, Aniridia, Genitourinary malformation, men-
tal Retardation) and Denys-Drash syndromes (Gessler et al.,
1990; Haber et al., 1990; Pelleteir et al., 1991a; Pelletier et al.,
1991b). At present, we cannot state that this growth
regulatory gene is implicated in ovarian carcinogenesis. How-
ever, its restricted tissue-specific expression in adults (gonads,
kidney, uterus, spleen and peritoneal layers between organs)
and, in particular, the very high WT-1 expression levels
observed in granulosa and epithelial cells ofthe normal ovary
(Pelleteir et al., 1991c), suggest that loss of a WT-1 allele may
contribute to the aetiology of the lIpl3 deleted ovarian
tumours.
The second hot spot of gene deletion in ovarian car-
cinomas, mapping on band llpl5.5 and telomeric to the P
Globin gene, corresponds to chromosome location of the
putative WT-2, initially associated with the Beckwith
Wiedemann syndrome (Koufos et al., 1989). At present, there
is no information about DNA sequences on Ipl15.5 possibly
involved in Wilms, ovarian and other tumours. According to
other authors (Ehlen & Dubeau, 1990; Lee et al., 1990;
Zheng et al., 1991) we found a remarkably high percentage
of allelic losses (47%) at the Ha-rasl locus. However, Ha-
rasl LOH is unlikely to imply a direct role of such oncogene
in ovarian carcinogenesis since genetic alterations were never
detected at the retained allele (van't Veer et al., 1988; Viel et
al., 1991). More probably, Ha-rasl LOH marks allelic loss of
adjacent genomic sequences functionally involved in ovarian
tumourigenesis. We are currently analysing, in ovarian car-
cinomas, the role of the gene encoding insulin like-growth
factor II (IGF2), which maps close to Ha-rasl and whose
expression is altered in Wilms, rhabdomyosarcomas and
hepatoblastomas, malignancies also characterised by IIpI5.5
LOH (Scott et al., 1985).
We do not know if the two putative tumour suppressor
genes have similar functions in ovarian carcinogenesis. How-
ever, their independent deletion in some tumours of our
series, as well as in Wilms tumours (Wadey et al., 1990),
suggests that they can contribute independently to the step-
wise development of the fully malignant phenotype.
Moreover, the concomitant deletion of both genomic regions
in some tumours (Henry et al., 1989), such as tumours 8-RR,
13-ZE and 40-PL with two separated areas of deletion,
indicates that the two genes may act synergistically. At pres-
ent, our analysis does not allow us to establish if the two lp
deletions in 8-RR, 13-ZE and 40-PL, but also in the other
ovarian tumours with deletions extending apparently uninter-
rupted from lIpl3 to lIpl5.5, occurred on one chromosome
or were derived from alternate deletions involving both
paternal and maternal chromosomes. In any case, the high
frequency of the concomitant lipl3 and lIpl5.5 deletions
suggests the importance of this event in ovarian car-
cinogenesis.
Correlations with clinicopathological parameters demon-
strated that in the group of patients with the loss of lIp
alleles in their tumour (18 cases), 61% had a diagnosis of
liver and/or gallbladder metastasis, whereas this infiltration
was present in only 11% of the patients with lp non deleted
tumours. The statistically significant association we observed
between liver metastasis and loss of lip polymorphic loci,
leads us to hypothesise that in ovarian cancer the presumed
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Ilp oncosuppressor genes are involved in tumour progression
rather than initiation. The biological significance of this cor-
relation could be interpreted with the acquisition of a partic-
ular metastatic phenotype (ability to colonise the liver) by the
tumour cells which lose Ilp genes. According to this
hypothesis patient RA, free of metastatic liver invasion, did
not display such allelic losses in none of the two peritoneal
tumour samples (16-RA and 17-RA); patient RR displayed
Ilp LOH late in the tumour evolution (tumour 8-RR), when
a liver metastasis was diagnosed; finally patient ZE developed
lip LOH in her primary tumour (13-ZE) before clinical
diagnosis ofhepatic metastasis. These observations bring into
question the possibility of a predictive role of lIp LOH
analysis in the identification of patients at high risk to
develop liver metastasis. More extensive studies, however, are
required to reach a firm conclusion on this point and we are
planning to extend this study to a larger number of new
selected cases to define the reliability of this molecular
marker.
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